Evidence based vaccinology

Vaccine

Volumn 20, Issue 11-12, 2002, Pages 1624-1630

  Nalin, David R ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Evidence based vaccinology; Manufacture; Vaccine development

Indexed keywords

VACCINE;

ARTICLE; CLINICAL RESEARCH; COST BENEFIT ANALYSIS; DECISION MAKING; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG MONITORING; DRUG SAFETY; DRUG SCREENING; EVIDENCE BASED MEDICINE; LICENSING; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; STANDARD; VACCINATION; VACCINE PRODUCTION; VALIDATION PROCESS;

CLINICAL TRIALS; COST-BENEFIT ANALYSIS; DRUG APPROVAL; DRUG INDUSTRY; EVIDENCE-BASED MEDICINE; HUMANS; VACCINES;

EID: 0037154726     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00481-9     Document Type: Article

References (53)

1. International trends in clinical laboratory testing
2. Evidence-based vaccinology: The work of the Cochrane vaccines field
3. Evidence based medicine
4. The vaccine adverse event reporting system (VAERS)
5. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines
6. Vaccine safety datalink team. Risk of chronic arthropathy among women after rubella vaccination
7. Quality assessment of DNA vaccines: Hepatitis-B vaccine
8. Postmarketing evaluation of the safety and effectiveness of varicella vaccine
9. Vaccines and risks: The responsibility of the media, scientists and clinicians
10. Ileal lymphoid nodular hyperplasia, nonspecific colitis and pervasive developmental disorder in children
11. An attempt to swindle nature: Press anti-immunisation reportage, 1993-1997
12. Cost-benefit analysis for hepatitis A vaccine
13. Screening policy for travellers from Rotterdam for hepatitis A antibodies prior to eventual immunization: Favourable cost-benefit ratio
14. Lag between discovery and production of new vaccines for the developing world
15. Evaluating the cost-effectiveness of interventions designed to increase the utilization of evidence-based guidelines
16. Is travel prophylaxis worth while? Economic appraisal of prophylactic measures against malaria, hepatitis A, and typhoid in travellers
17. Cost benefit analysis of the introduction of mass vaccination against hepatitis B in Italy
18. Poliomyelitis prevention in the United States: Introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the advisory committee on immunization practices
19. Pertussis: The disease and the vaccine
20. Vaccine-induced autoimmunity
21. Randomized trials should be interpreted carefully
22. Evidence-based medicine from the point of view of health insurance companies: A frame for qualified freedom of therapy and an improved economy?
23. Development and implementation of evidence-based guidelines: A multisite demonstration project
24. Rationing in public health: What criteria, what priorities?
25. Evidence-based health policy-making, hospital funding and health insurance
26. Implementing evidence-based medicine: What effects are measurable?
27. A scandal of inaction: How to help GPs implement evidence-based health promotion
28. An integrated program for evidence-based medicine in medical school
29. Prevalence of use of complementary/alternative medicine: A systematic review
30. Practice guidelines - Legal aspects
31. The physician healer: Ancient magic or modern science?
32. Clinical mumps vaccine efficacy
33. Epidemiologic methods in immunization programs
34. Fraud and misconduct in medical research
35. Misconduct in medical research. A questionnaire survey among project leaders in health region 4
36. Dishonesty in medical research. A questionnaire study among project administrators in health region 4
37. Misrepresentation and responsibility in medical research
38. Medical investigators' views about ethics and fraud in medical research
39. An overview of the vaccine adverse event reporting system as a surveillance system
40. The postmarketing safety profile of varicella vaccine
41. Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children
42. Resurgence of mumps in Singapore caused by the Rubini mumps virus vaccine strain
43. Pneumococcal vaccine - Past, present, and future
44. Bovine sera used in the manufacture of biologicals: Current concerns and policies of the US Food and Drug Administration regarding the transmissible spongiform encephalopathies
45. Vaccines for biodefense: A system in distress